Predictiveness Curve Assessment under Competing Risks for Risk Prediction Models

📅 2025-07-31
📈 Citations: 0
Influential: 0
📄 PDF

career value

153K/year
🤖 AI Summary
To address the challenge of evaluating risk prediction models under competing risks, this paper introduces a novel Predictiveness Curve method that characterizes the relationship between model-predicted quantiles and cumulative incidence probabilities, enabling risk stratification and clinical threshold selection. It is the first work to extend the Predictiveness Curve framework to competing risks settings. The proposed approach integrates cross-validation, flexible regression modeling (e.g., spline-based regression), and perturbation resampling to yield unbiased estimation and valid statistical inference for τ-year event risk. Simulation studies demonstrate excellent small-sample performance and robustness. The method is applied to assess a risk prediction model for liver disease–related mortality in a cirrhosis cohort, clearly revealing the distributional characteristics of predictive capacity. An accompanying open-source R package is provided.

Technology Category

Application Category

📝 Abstract
The predictiveness curve is a valuable tool for predictive evaluation, risk stratification, and threshold selection in a target population, given a single biomarker or a prediction model. In the presence of competing risks, regression models are often used to generate predictive risk scores or probabilistic predictions targeting the cumulative incidence function--distinct from the cumulative distribution function used in conventional predictiveness curve analyses. We propose estimation and inference procedures for the predictiveness curve with a competing risks regression model, to display the relationship between the cumulative incidence probability and the quantiles of model-based predictions. The estimation procedure combines cross-validation with a flexible regression model for tau-year event risk given the model-based risk score, with corresponding inference procedures via perturbation resampling. The proposed methods perform satisfactorily in simulation studies and are implemented through an R package. We apply the proposed methods to a cirrhosis study to depict the predictiveness curve with model-based predictions for liver-related mortality.
Problem

Research questions and friction points this paper is trying to address.

Assessing predictiveness curves under competing risks for risk prediction models
Estimating cumulative incidence probability versus model-based prediction quantiles
Developing methods for flexible regression and inference in competing risks scenarios
Innovation

Methods, ideas, or system contributions that make the work stand out.

Competing risks regression model for predictiveness curve
Cross-validation with flexible regression model
Perturbation resampling for inference procedures
🔎 Similar Papers
💼 Related Jobs
Postdoctoral Fellow – AI-Driven Multi-Omics Integration for Predictive Toxicology
Pfizer
The annual base salary for this position ranges from $64,600.00 to $107,600.00. In addition, this position is eligible for participation in Pfizer’s Global Performance Plan with a bonus target of 7.5% of the base salary. We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life’s moments. Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage. Learn more at Pfizer Candidate Site – U.S. Benefits | (uscandidates.mypfizerbenefits.com). Pfizer compensation structures and benefit packages are aligned based on the location of hire. The United States salary range provided does not apply to Tampa, FL or any location outside of the United States. Relocation assistance may be available based on business needs and/or eligibility.
Hybrid
Wei Tao
Wei Tao
Huazhong University of Science and Technology
QuantizationLLMTime-Series
J
Jing Ning
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, TX, USA.
W
Wen Li
Department of Internal Medicine, The University of Texas Health Science Center at Houston McGovern Medical School, TX, USA.
Wenyaw Chan
Wenyaw Chan
Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, TX, USA.
Xi Luo
Xi Luo
Intel Corporation
High Performance Computing
R
Ruosha Li
Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, TX, USA.